The latest from Magnitude Biosciences

A fully-fledged pre-clinical contract services provider.
Here’s what we’ve been up to along the way!

15 November 2022

Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services

Mira Nair

Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevity, nutraceuticals and pharmaceutical industries, has closed a fourth round of investment to accelerate the scaling of its business.

7 October 2022

Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth

Jessica Evans

No Comments

North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growth of the world leading C. elegans CRO.

26 September 2022

C. elegans capabilities in the toxicology field

Guillermo Navarrete

No Comments

C. elegans is a proven model for toxicology research and has numerous advantages over other animal models

18 September 2022

SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics

Jessica Evans

No Comments

Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for ageing therapeutics.

23 August 2022

AB Biotek works with Magnitude Biosciences to accelerate probiotics development

indigo

No Comments

Magnitude Biosciences worked with the AB Biotek HNH scientific team to design and implement novel techniques for testing the health impact of probiotics. Download the case study for the full detail on how worms can be used to accelerate microbiome research.

24 March 2022

Ageing drug discovery biotech sees exciting early in vivo data for lead compound

Holly Winskell

No Comments

Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease.

Blog Post Press Release

Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services

Blog Post Press Release

Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth

Blog Post

C. elegans capabilities in the toxicology field

Blog Post Press Release

SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics

Blog Post

Ageing drug discovery biotech sees exciting early in vivo data for lead compound

Press Release

Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing

news Publication

Frontiers in Aging: Applying C. elegans to industrial drug discovery

Press Release

Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting...

Press Release

Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand

Blog Post

Could C. elegans be the key to slowing ageing?

1 2 3 Next »

Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services

Mira Nair Nov 15, 2022

Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More

Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth

Jessica Evans Oct 7, 2022

North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More

Blog Post

C. elegans capabilities in the toxicology field

Guillermo Navarrete Sep 26, 2022

C. elegans is a proven model for toxicology research and has numerous advantages over other animal m...Read More

animal model, DART, ethical, Toxicology

SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics

Jessica Evans Sep 18, 2022

Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More

Blog Post

Ageing drug discovery biotech sees exciting early in vivo data for lead compound

Holly Winskell Mar 24, 2022

Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease. ...Read More

Press Release

Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing

Holly Winskell Jan 31, 2022

The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More

Frontiers in Aging: Applying C. elegans to industrial drug discovery

Mira Nair Oct 28, 2021

Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More

ageing, Aging

Press Release

Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms

Holly Winskell Aug 23, 2021

The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More

Press Release

Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand

Holly Winskell Jul 29, 2021

Hannah Raddings (right) and Alana Mullins (centre) with Magnitude Biosciences Head of Experiments Mi...Read More

Blog Post

Could C. elegans be the key to slowing ageing?

Holly Winskell Jul 26, 2021

Originally published in Health Tech World: https://www.htworld.co.uk/interviews/could-c-elegans-be-t...Read More

Blog Post

Frontiers in Longevity: How do we slow human ageing?

Holly Winskell Jul 19, 2021

How do we slow the process of Ageing? David Weinkove discusses learnings from the Clubhouse event "T...Read More

Blog Post

Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting

Holly Winskell Jul 9, 2021

Some fascinating ideas came out of the Translating Ideas Into Therapies meeting held June 30-July 1 ...Read More

Blog Post

Unlocking the microbiome as a target for drug discovery using C. elegans

Holly Winskell Jul 8, 2021

The human microbiome holds great promise for modern medicine but is still largely a mystery to scie...Read More

news

Magnitude Biosciences recognised in Developed in Durham as local success story

Holly Winskell Jun 7, 2021

Magnitude Biosciences has been recognised by Developed in Durham....Read More

Event

Magnitude Biosciences to attend Translating Ideas Into Therapies 2021 and the International C. elegans Conference in June 2021

Holly Winskell Jun 3, 2021

June 2021 marks an exciting month as we see some of our C. elegans thought leaders speaking at key e...Read More

Blog Post

A child, a worm, and a new era of drug discovery

Mira Nair May 27, 2021

This article will tell the story of how C. elegans enabled a life-changing effects drug therapy for ...Read More

Blog Post

Magnitude Biosciences launches new website

Mira Nair May 22, 2021

Magnitude Biosciences, the world’s leading C. elegans Contract Research Organisation (CRO) and com...Read More

Press Release

Magnitude Biosciences secures its second round of funding to support its pre-clinical research services

Magnitude Bioscience Apr 16, 2021

Biosciences spinout secures six-figure funding to create new North East jobs A spinout enterprise fr...Read More

Event

Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, Paris.

Magnitude Bioscience Apr 16, 2021

Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, P...Read More

Press Release

Magnitude Biosciences announces new hires to support continued growth

Magnitude Bioscience Apr 7, 2021

Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More